RxDoctor Payments Data

Julie Pelletier

Community Health · Fitchburg, MANPI 1649718198

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 32.7% of the total. Among community health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,026in general payments, 2019–2025

Across 46 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$335
  • Valinor Pharma, LLC$226
  • Alkermes, Inc.$154
  • Indivior Inc.$128
  • Lundbeck LLC$75
  • Boston Scientific$51
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$1,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,026 in reported general payments places this provider in the 95th percentile of 26 community health providers in Massachusetts.

See all community health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$25,325
Medicare patients
130
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine278$62,416
BelbucaBuprenorphine Hcl61$42,762
RelistorMethylnaltrexone Bromide13$34,163
MovantikNaloxegol Oxalate74$31,817
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl198$27,117
Gabapentin740$8,797
Lidocaine107$7,697
ButransBuprenorphine11$5,593
Pregabalin385$5,431
Cyclobenzaprine Hcl303$3,344
Duloxetine Hcl175$3,312
Diclofenac Sodium119$2,649
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen244$2,484
Celecoxib83$2,179
Naloxone Hcl36$2,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$335$34,16313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 community health providers in Massachusetts.

Other community health in Fitchburg

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →